M
Marco Valgimigli
Researcher at University of Bern
Publications - 772
Citations - 91095
Marco Valgimigli is an academic researcher from University of Bern. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 105, co-authored 696 publications receiving 69184 citations. Previous affiliations of Marco Valgimigli include University of Düsseldorf & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
Stylianos A. Pyxaras,Lukas Hunziker,Alaide Chieffo,Emanuele Meliga,Azeem Latib,Seung-Jung Park,Yoshinobu Onuma,Piera Capranzano,Marco Valgimigli,Inga Narbute,Raj Makkar,Igor F. Palacios,Young-Hak Kim,Piotr P. Buszman,Tarun Chakravarty,Imad Sheiban,Roxana Mehran,Ronan Margey,Arvind K. Agnihotri,Sebastiano Marra,Davide Capodanno,Martin B. Leon,Jeffrey W. Moses,Jean Fajadet,Thierry Lefèvre,Marie-Claude Morice,Andrejs Erglis,Corrado Tamburino,Ottavio Alfieri,Patrick W. Serruys,Antonio Colombo,Christoph Naber +31 more
TL;DR: In this paper, the authors compared the long-term clinical outcome after percutaneous coronary intervention (PCI) with first-generation drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) in patients with acute coronary syndrome (ACS).
Journal ArticleDOI
Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study
Gladys N. Janssens,Maarten A.H. van Leeuwen,Nina W. van der Hoeven,Guus A. de Waard,Robin Nijveldt,Roberto Diletti,Felix Zijlstra,Clemens von Birgelen,Javier Escaned,Marco Valgimigli,Niels van Royen +10 more
TL;DR: The REDUCE-MVI study will establish whether ticagrelor as a maintenance therapy may improve microvascular function in patients after revascularized STEMI.
Journal ArticleDOI
Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study.
Marco Valgimigli,Athanasios Patialiakas,Attila Thury,Salvatore Colangelo,Gianluca Campo,Matteo Tebaldi,Imre Ungi,Stefano Tondi,Marco Roffi,Alberto Menozzi,Nicoletta De Cesare,Roberto Garbo,Emanuele Meliga,Luca Testa,Henrique Mesquita Gabriel,Flavio Airoldi,Marco Ferlini,Francesco Liistro,Dellavalle A,Pascal Vranckx,Carlo Briguori +20 more
TL;DR: The ZEUS trial as mentioned in this paper showed that drug-eluting stent (DES) implantation followed by a shorter than currently recommended course of dual antiplatelet therapy (DAPT) will decrease the incidence of 12-month major adverse cardiovascular events as compared with BMS in undefined DES recipients.
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of
Marco Roffi,Carlo Patrono,Jean-Philippe Collet,Christian Mueller,Marco Valgimigli,Felicita Andreotti,Jeroen J. Bax,Michael A. Borger,Carlos Brotons,Derek P. Chew,Baris Gencer,Gerd Hasenfuss,Keld Kjeldsen,Patrizio Lancellotti,Ulf Landmesser,Julinda Mehilli,Debabrata Mukherjee,Robert F. Storey,Stephan Windecker,Helmut Baumgartner,Oliver Gaemperli,Stephan Achenbach,Stefan Agewall,Lina Badimon,Colin Baigent,Héctor Bueno,Raffaele Bugiardini,Scipione Carerj,Filip Casselman,Thomas Cuisset,Çetin Erol,Donna Fitzsimons,Martin Halle,Christian W. Hamm,David Hildick-Smith,Kurt Huber,Efstathios Iliodromitis,Stefan James,Basil S. Lewis,Gregory Y.H. Lip,Massimo F Piepoli,Dimitrios J. Richter,Thomas Rosemann,Udo Sechtem,Ph. Gabriel Steg,Christian Vrints,José Luis Zamorano +46 more
Journal ArticleDOI
Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial
Giuseppe Ferrante,Patrizia Presbitero,Elena Corrada,Gianluca Campo,Leonardo Bolognese,Corrado Vassanelli,Salvatore Colangelo,Nicoletta De Cesare,Alfredo E. Rodriguez,Ezio Bramucci,Raúl Moreno,Tommaso Piva,Imad Sheiban,Giampaolo Pasquetto,Francesco Prati,Marco Stefano Nazzaro,Roberto Ferrari,Marco Valgimigli +17 more
TL;DR: In this analysis, the clinical benefit of SES use, over BMS, at 3-year follow-up was restricted to men and was not observed among women.